10-Q: Acro Biomedical Q1 2026: No Revenue, Growing Losses

Acro Biomedical Co., Ltd. reported no revenue for the first quarter of 2026, with net losses widening to $43,774, primarily due to operating expenses and interest on related party loans.

Summary

• Acro Biomedical Co., Ltd. reported no revenue for the first quarter ended March 31, 2026, similar to the same period in 2025.
• Operating expenses increased significantly to $60,271 in Q1 2026 from $8,934 in Q1 2025, largely due to public company costs.
• The company recorded a $20,000 gain from liability extinguishment in Q1 2026.
• Net loss for the quarter was $43,774, an increase from $10,301 in the prior year's quarter.
• Basic and diluted loss per share remained at $(0.00) for both periods.
• Cash reserves decreased to $3,873 as of March 31, 2026, from $4,098 as of December 31, 2025.
• The company continues to rely on advances from a minority stockholder for funding.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to its lack of revenue, operating losses, and negative cash flow.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this filing as extremely negative due to the complete absence of revenue, widening losses, and substantial doubt about the company's ability to continue as a going concern.

Positives

• Recorded a $20,000 gain from liability extinguishment in the first quarter of 2026.
• Advances from a minority stockholder continue to provide necessary funding for operations.

Negatives

• No revenue generated in the first quarter of 2026, consistent with the prior year.
• Net loss increased to $43,774 in Q1 2026 from $10,301 in Q1 2025.
• Operating expenses more than six-fold increase to $60,271 in Q1 2026 from $8,934 in Q1 2025.
• Stockholders' deficit widened to $427,235 as of March 31, 2026, from $386,964 as of December 31, 2025.
• Cash balance decreased to $3,873 as of March 31, 2026.
• Substantial doubt about the company's ability to continue as a going concern.
• Lack of an active trading market for its common stock, with quotes reflecting only unsolicited customer orders.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to no revenue, operating losses, negative cash flow, and a stockholders' deficit.
• The company may not be able to raise necessary funds for capital expenditures, working capital, and other cash requirements due to its financial condition, lack of sales, and absence of an active trading market for its stock.
• Reliance on advances from a minority stockholder for funding, with no assurance of continued support.
• Potential for significant dilution to existing stockholders if funds are raised through equity issuance.
• Inability to develop or market products, which could lead to continued inability to generate revenue.
• Inflationary pressures and supply chain disruptions could increase costs and potentially affect product pricing, although the company has not made sales or purchased inventory since December 31, 2022.
• The company's stock is traded on the OTC Market Groups Pink Limited Market, making it an unsolicited-only stock with no market makers, leading to higher risk of wider spreads, increased volatility, and price dislocations, making it difficult for investors to sell.
• The company has no full-time employees and its sole employee, the CEO, works part-time without compensation, raising concerns about operational capacity and internal controls.

Future Outlook

The company has no revenue and significant operating losses, raising substantial doubt about its ability to continue as a going concern. Future operations are dependent on obtaining additional funds, implementing business plans, and generating revenue, for which there is no assurance. The company will continue to rely on advances from a minority stockholder.

Management Comments

• The company's disclosure controls and procedures were not effective as of March 31, 2026, due to the inadequacy of internal controls, the sole employee being the CEO and CFO, and a limited internal audit function.
• Management has determined that internal controls contain material weaknesses due to the absence of segregation of duties, lack of qualified accounting personnel, and excessive reliance on third-party consultants.
• The company has no full-time employees and its CEO works part-time without compensation.

Industry Context

StockSavvy.ai notes that Acro Biomedical operates in the nutritional products sector, specifically focusing on cordyceps, a traditional Chinese medicine ingredient. The company's lack of revenue and ongoing losses, coupled with its reliance on related party financing, highlight significant operational and financial challenges. This situation is particularly concerning given the general trend towards growth and innovation in the health and wellness industry, where companies typically demonstrate revenue generation and a path to profitability.

Comparison to Industry Standards

• Companies in the broader health and wellness sector, particularly those involved with natural supplements like cordyceps, typically aim for consistent revenue generation and positive gross margins. Acro Biomedical's complete absence of revenue for multiple periods falls far below industry standards.
• Competitors in the nutraceutical market often invest heavily in research and development, marketing, and sales infrastructure to capture market share. Acro Biomedical's limited operational capacity, with no full-time employees and no active product development generating revenue, is not comparable to industry leaders.
• Established players in the supplement industry often have robust supply chains and distribution networks. Acro Biomedical's historical reliance on a few suppliers and customers, and its current lack of orders, indicates a significant deficit in operational scale compared to industry benchmarks.

Corporate Governance

Related Party Transactions

• The company owed $1,100 to a former chief executive officer for non-interest-bearing advances and expenses as of March 31, 2026.
• A minority stockholder paid $49,596 in expenses on behalf of the company during the three months ended March 31, 2026.
• The company owed $374,008 to the minority stockholder for non-interest-bearing advances and expenses as of March 31, 2026.
• Imputed interest of $3,503 was recorded on advances from the minority stockholder for the three months ended March 31, 2026.
• Total amounts due to related parties were $375,108 as of March 31, 2026.

Stakeholder Impact

• Shareholders face significant risk due to the company's precarious financial position, lack of revenue, widening losses, and substantial doubt about its going concern status. The lack of an active trading market also makes it difficult to sell shares.
• Creditors and suppliers may face uncertainty regarding timely payment given the company's negative working capital and reliance on related party financing.
• Employees (currently only the CEO working part-time without compensation) are impacted by the company's lack of operational stability and potential for continued financial distress.

Next Steps

• The company must obtain additional funds and implement its business plans to continue operations.
• The company will continue to rely on advances from a minority stockholder for funding.

Key Dates

Recommendation

The company exhibits a complete lack of revenue, increasing losses, and significant going concern issues. The reliance on related party financing and the absence of a clear path to profitability or product development make it a highly speculative investment with substantial downside risk. The lack of an active trading market further exacerbates liquidity concerns for investors.

Keywords

Acro Biomedical, 10-Q, Quarterly Report, Financial Statements, Going Concern, No Revenue, Operating Loss, Related Party Transactions, Minority Stockholder, Nevada Corporation, Cordyceps Products